» Articles » PMID: 11532983

Fumarylacetoacetate, the Metabolite Accumulating in Hereditary Tyrosinemia, Activates the ERK Pathway and Induces Mitotic Abnormalities and Genomic Instability

Overview
Journal Hum Mol Genet
Date 2001 Sep 5
PMID 11532983
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer. We report that a sub-apoptogenic dose of fumarylacetoacetate (FAA), the mutagenic metabolite accumulating in HT1, induces spindle disturbances and segregational defects in both rodent and human cells. Mitotic abnormalities, such as distorted spindles, lagging chromosomes, anaphase/telophase chromatin bridges, aberrant karyokinesis/cytokinesis and multinucleation were observed. Some mitotic asters displayed a large pericentriolar material cloud and/or altered distribution of the spindle pole-associated protein NuMA. FAA-treated cells developed micronuclei which were predominantly CREST-positive, suggesting chromosomal instability. The Golgi complex was rapidly disrupted by FAA, without evident microtubules/tubulin alterations, and a sustained activation of the extracellular signal-regulated protein kinase (ERK) was also observed. Primary skin fibroblasts derived from HT1 patients, not exogenously treated with FAA, showed similar mitotic-derived alterations and ERK activation. Biochemical data suggest that FAA causes ERK activation through a thiol-regulated and tyrosine kinase-dependent, but growth factor receptor- and protein kinase C-independent pathway. Pre-treatment with the MEK inhibitor PD98059 and the Ras farnesylation inhibitor B581 decreased the formation of CREST-positive micronuclei by approximately 75%, confirming the partial contribution of the Ras/ERK effector pathway to the induction of chromosomal instability by FAA. Replenishment of intracellular glutathione (GSH) with GSH monoethylester abolished ERK activation and reduced the chromosomal instability induced by FAA by 80%. Together these results confirm and extend the previously reported genetic instability occurring in cells from HT1 patients and allow us to speculate that this tumorigenic-related phenomenon may rely on the biochemical/cellular effects of FAA as a thiol-reacting and organelle/mitotic spindle-disturbing agent.

Citing Articles

Pediatric Hepatocellular Carcinoma: A Review of Predisposing Conditions, Molecular Mechanisms, and Clinical Considerations.

Young E, ONeill A, Rangaswami A Int J Mol Sci. 2025; 26(3).

PMID: 39941018 PMC: 11818592. DOI: 10.3390/ijms26031252.


Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation.

Kehar M, Sen Sarma M, Seetharaman J, Jimenez Rivera C, Chakraborty P Can Liver J. 2024; 7(1):54-63.

PMID: 38505790 PMC: 10946188. DOI: 10.3138/canlivj-2023-0018.


Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

El-Karaksy H, Abdullatif H, Ghobrial C, Mogahed E, Yasin N, Talal N PLoS One. 2022; 17(5):e0268017.

PMID: 35536841 PMC: 9089876. DOI: 10.1371/journal.pone.0268017.


Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study.

Megdadi N, Almigdad A, Alakil M, Alqiam S, Rababah S, Dwiari M Int J Pediatr. 2021; 2021:3327277.

PMID: 34899923 PMC: 8660245. DOI: 10.1155/2021/3327277.


Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Tang Y, Kong Y Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):514-523.

PMID: 34704422 PMC: 8777462. DOI: 10.3724/zdxbyxb-2021-0255.